Fig. 1From: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialKaplan–Meier analysis of overall survival and relapse-free survival from the time of randomization. From Wei et al. [22]. Copyright © (2021) Massachusetts Medical Society. Reprinted with permissionBack to article page